DIA Biosimilars 2013

Articles Published in 2008

Veeda Expands Global Capacity with New Oncology CRO

Thursday, May 1, 2008 04:50 PM

Ahmedabad-based CRO Veeda Clinical Research, launched a new division, called Global Oncology CRO, to concentrate on cancer research while leveraging Veeda’s operational capacities in the United States, Europe and India. The oncology subsidiary will be led by its president and chief executive officer, Matt Bowman. The new business will be headquartered in Columbus, Ohio. Kathy Squillace was named to the position of vice president of clinical operations and Dave Colborn was made vice president of data management and information technology.

More... »

Cenduit: Now with Patient Reminders

New England Research Institutes Partners With Evidence

Monday, April 28, 2008 10:45 AM

Watertown, Mass.-based CRO New England Research Institutes (NERI) established a strategic partnership with Evidence Clinical and Pharmaceutical Research Institute, a CRO which focuses on conducting trials in Russia and Eastern Europe. Evidence is headquartered in Saint-Petersburg, Russia, and has offices in Los Altos, Calif., and Swampscott, Mass. The companies stated that both Eastern Europe and Russia are becoming increasingly popular regions for conducting clinical trials, and sponsors are creating an ever larger presence there.

More... »

CRF Health – eCOA Forum

CWWeekly April 21st 2008 Issue

Friday, April 25, 2008 01:52 PM

Top News

More... »

Recent Industry Personnel Changes

Thursday, April 24, 2008 01:48 PM

Contract Research

More... »

Bio's National Investor Conference Plays Matchmaker

Wednesday, April 23, 2008 12:21 PM

CenterWatch ‘watched’ as more than 60 emerging biotech companies and 125 venture capitalists from across the U.S. converged at the 1st annual BIO National Venture Conference in Boston this week.

More... »

CWWeekly April 14th 2008 Issue

Saturday, April 19, 2008 12:07 PM

Top News

More... »

Magic Johnson—Celebrity Spokesperson for Minority Patient Recruitment?

Friday, April 18, 2008 12:18 PM

Earvin “Magic” Johnson, NBA champion and chairman and chief executive officer of the Johnson Development Corp., came to IIR’s 17th Annual Partnerships with CROs in Las Vegas, Nevada, with a mission—to urge pharma to increase minority participation in clinical trials. But, he left, quite possibly, with an even bigger mission—to become a celebrity spokesperson for minority patient recruitment.

More... »

CenterWatch Monthly April 2008 Issue

Thursday, April 17, 2008 04:14 PM

FDA Debarment Failures a Wake-Up Call for CROs, Drug Sponsors

More... »

Coast IRB Receives FDA Warning Letter

Tuesday, April 15, 2008 11:42 AM

Coast IRB, an independent institutional review board (IRB) based in Colorado Springs, Colo., received a Warning Letter from the U.S. Food and Drug Administration (FDA) concerning the company’s improper expedited review of a phase I study being conducted in northern California. In an unusual move, the agency has temporarily suspended the IRB’s ability to do expedited reviews.

More... »

CWWeekly April 7th 2008 Issue

Friday, April 11, 2008 05:12 PM

Top News

More... »

`
CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs